ID   M397-AR
AC   CVCL_XK13
SY   M397AR
DR   cancercelllines; CVCL_XK13
DR   Wikidata; Q95984253
RX   PubMed=24735930;
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_XK00 ! M397
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 19-12-24; Version: 7
//
RX   PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505;
RA   Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M.,
RA   Comin-Anduix B., Ribas A.;
RT   "Effects of AKT inhibitor therapy in response and resistance to BRAF
RT   inhibition in melanoma.";
RL   Mol. Cancer 13:83.1-83.14(2014).
//